LA 419 | CAS#263754-97-8 | nitric oxide donor

MedKoo Cat#: 598169 | Name: LA 419

Description:

WARNING: This product is for research use only, not for human or veterinary use.

LA 419 is a nitric oxide donor.

Chemical Structure

LA 419

CAS#263754-97-8

Theoretical Analysis

MedKoo Cat#: 598169

Name: LA 419

CAS#: 263754-97-8

Chemical Formula: C14H18N2O7S

Exact Mass: 358.0835

Molecular Weight: 358.36

Elemental Analysis: C, 46.92; H, 5.06; N, 7.82; O, 31.25; S, 8.95

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

LA 419; LA-419; LA419;

IUPAC/Chemical Name

(3S,3aR,6R,6aS)-6-(nitrooxy)hexahydrofuro[3,2-b]furan-3-yl 2-(ethylthio)-1,2-dihydropyridine-3-carboxylate

InChi Key

ISKSFVDWBALXEP-ZLUZDFLPSA-N

InChi Code

InChI=1S/C14H18N2O7S/c1-2-24-13-8(4-3-5-15-13)14(17)22-9-6-20-12-10(23-16(18)19)7-21-11(9)12/h3-5,9-13,15H,2,6-7H2,1H3/t9-,10+,11+,12+,13?/m0/s1

SMILES Code

CCSC1NC=CC=C1C(O[C@H]2CO[C@@H]3[C@H](O[N+]([O-])=O)CO[C@H]23)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 358.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Mourelle M, Martin MT, Giménez F. Treatment with LA-419 prevents monocrotaline-induced pulmonary hypertension and lung injury in the rat. Proc West Pharmacol Soc. 2011;54:89-93. PubMed PMID: 22423590. 2: Megson IL, Leslie SJ. LA-419, a nitric-oxide donor for the treatment of cardiovascular disorders. Curr Opin Investig Drugs. 2009 Mar;10(3):276-85. Review. PubMed PMID: 19333886. 3: Martínez-Murillo R, Fernández AP, Serrano J, Rodrigo J, Salas E, Mourelle M, Martínez A. The nitric oxide donor LA 419 decreases brain damage in a focal ischemia model. Neurosci Lett. 2007 Mar 26;415(2):149-53. Epub 2007 Jan 7. PubMed PMID: 17239538. 4: Serrano J, Fernández AP, Martínez-Murillo R, Alonso D, Rodrigo J, Salas E, Mourelle M, Martínez A. The nitric oxide donor LA 419 decreases ischemic brain damage. Int J Mol Med. 2007 Feb;19(2):229-36. PubMed PMID: 17203196. 5: Porras M, Martín MT, Terán E, Mourelle M, Vergara P. The nitric oxide donor LA-419 [S-(6-Nitro-oxi-hexahydro-furo[3,2-b]furan-3-1-il)thioacetate] prevents intestinal dysmotility, bacterial translocation, and inflammation in a rat model of enteritis. J Pharmacol Exp Ther. 2008 Feb;324(2):740-8. Epub 2007 Oct 24. PubMed PMID: 17959746. 6: Paulis L, Simko F. LA419, a novel nitric oxide donor, prevents cardiac remodeling via the endothelial nitric oxide synthase pathway: NO donors as a means of antiremodeling. Hypertension. 2007 Dec;50(6):1009-11. Epub 2007 Nov 5. PubMed PMID: 17984370. 7: Peña E, Padro T, Molins B, Vilahur G, Badimon L. Proteomic signature of thrombin-activated platelets after in vivo nitric oxide-donor treatment: coordinated inhibition of signaling (phosphatidylinositol 3-kinase-γ, 14-3-3ζ, and growth factor receptor-bound protein 2) and cytoskeleton protein translocation. Arterioscler Thromb Vasc Biol. 2011 Nov;31(11):2560-9. doi: 10.1161/ATVBAHA.111.231852. PubMed PMID: 21836071. 8: Carnicer R, Guillén N, Arbonés-Mainar JM, Navarro MA, Guzmán MA, Barranquero C, Arnal C, Gascón S, Acín S, Mourelle M, Osada J. Nitric oxide-releasing agent, LA419, reduces atherogenesis in apolipoprotein E-deficient mice. Naunyn Schmiedebergs Arch Pharmacol. 2009 May;379(5):489-500. doi: 10.1007/s00210-008-0377-5. Epub 2008 Dec 3. PubMed PMID: 19050853. 9: Vilahur G, Pena E, Padró T, Badimon L. Protein disulphide isomerase-mediated LA419- NO release provides additional antithrombotic effects to the blockade of the ADP receptor. Thromb Haemost. 2007 Apr;97(4):650-7. PubMed PMID: 17393029. 10: Hernandez MR, Tonda R, Arderiu G, Pino M, Serradell M, Escolar G. Antithrombotic effect of a new nitric oxide donor (LA419) on experimental thrombogenesis. Eur J Clin Invest. 2005 May;35(5):337-42. PubMed PMID: 15860046. 11: Zafar MU, Vilahur G, Choi BG, Ibanez B, Viles-Gonzalez JF, Salas E, Badimon JJ. A novel anti-ischemic nitric oxide donor (LA419) reduces thrombogenesis in healthy human subjects. J Thromb Haemost. 2007 Jun;5(6):1195-200. PubMed PMID: 17389007. 12: Ruiz-Hurtado G, Fernández-Velasco M, Mourelle M, Delgado C. LA419, a novel nitric oxide donor, prevents pathological cardiac remodeling in pressure-overloaded rats via endothelial nitric oxide synthase pathway regulation. Hypertension. 2007 Dec;50(6):1049-56. Epub 2007 Nov 5. PubMed PMID: 17984372.